Introduction {#s1}
============

Hyperglycemia has been extensively studied in cell model and animal studies for its effect on immune system against infections \[[@CIT0001]\]. Several observational studies reported that diabetic patients with higher glycemic level were associated with an elevated risk of infections \[[@CIT0005], [@CIT0006]\]. However, these studies focused on diabetic patients alone (without nondiabetics as the comparison) and did not account for lifestyle risk factors, such as body mass index (BMI), cigarette smoking, and alcohol consumption. Therefore, the exact relation between blood glucose level and infection risk is yet to be determined, and it is unknown whether optimal glucose control could reduce the infection risk to the level comparable to that among nondiabetics. Although numerous studies examined the association between high blood glucose level and risk of infection at specific site, few studies fully examined the risks across different sites of infection \[[@CIT0007]\]. Lastly, there were limited data on glucose control and infection risk in the elderly population, who have a higher infection risk and a less stringent A1c goal suggested by current practice guidelines. The answers to these questions have important clinical implications to set optimal glycemic control goal for infection prevention, as current recommendations regarding glycemic goal were based on micro-vascular complication prevention.

In the present study, we analyzed population-based community screening data to (1) investigate the risk of first hospitalization for any infection and individual site of infections across a wide range of fasting plasma glucose (FPG) level; (2) evaluate the relation between fasting glucose level and infection-related mortality; and (3) assess the relation between glycemic level and infection risk among older people. We hypothesized that a lower blood glucose level was associated with a lower risk of infection-related hospitalization and mortality.

METHODS {#s2}
=======

Data Source and Study Population {#s3}
--------------------------------

Potential participants of this prospective study came from a total of 125 865 individuals who voluntarily participated in a free community-based health screening service for the residents aged 40 years or older in New Taipei City for 2005--2008. In brief, the participants filled out the questionnaire about demographics, educational level, and lifestyle information. Each participant received a standard physical examination and blood and urine analyses. Overnight fasting blood and first morning voided urine were collected and analyzed. With participants' consent, the screening program database was linked to the National Health Insurance Database and the National Death Registry using each participant's unique national identification number. In Taiwan, national health insurance is compulsory for all residents, and the coverage rate for 2005--2008 was over 99%. After data linkage, information related to individual identification were removed and remained anonymous during the entire study process. The protocol was approved by the National Taiwan University Hospital Research Ethics Committee.

Participants were excluded if they did not have baseline measurement of FPG level or BMI; complete information about cigarette smoking, alcohol consumption, and education level; and any claims in the National Health Insurance Database. The final study population included 118 645 participants (see [Supplementary Figure 1](#sup1){ref-type="supplementary-material"} for study flow diagram).

Measurement of Diabetes and Other Covariates {#s4}
--------------------------------------------

The main exposure of this study was diabetes, which was defined by the following criteria: (1) FPG over 126 mg/dL or (2) prescription of any hypoglycemic agent (verified from the health insurance claims database) for more than 28 days in the previous year before the baseline survey. Participants who had treated or untreated diabetes were further classified by their FPG levels. Body mass index was categorized into the following categories: \<18.5, 18.5 to \<25, ≥25 to \<30, and ≥30 kg/m2. Age was categorized as 20 to 40 years, 41 to 50 years, 51 to 60 years, 61 to 70 years, and 71 to 100 years.

Information about other potential confounding factors were obtained from the questionnaire at cohort entry (BMI, age, sex, level of education, smoking and alcohol use) and from the National Health Insurance Database (comorbid diseases and prior hospitalization and drug use history during the 12-month period before study entry; the International Classification of Diseases, 9th revision, Clinical Modification \[ICD-9-CM\] codes provided in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Outcome and Follow-Up Plan {#s5}
--------------------------

The primary outcome of interest is incident hospitalization for all infections ascertained from the National Health Insurance Database after study beginning. Hospitalization for infection further was classified according to specific site of infection, including septicemia, lower respiratory tract, intra-abdominal, reproductive and urinary tract, skin and soft tissue, osteomyelitis, necrotizing fasciitis, central nervous system, and invasive mold, as defined by ICD-9-CM codes listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The patients may have more than 1 specific site of infection in their first hospitalization for infection. The secondary outcomes were overall mortality and infection-related mortality. The vital status and date of death for the study participants was obtained by linkage through the National Death Registry with the unique identification number. The cohort participants were followed up from the date of health screening until first hospitalization for infection, death (based on vital registry), or the end of 2014, whichever came first. Infection-related death was defined by the death certificates codes (underlying cause of death) according to ICD-9 and ICD-10, using data from the vital registry. In the analysis for infection-related deaths, all participants were followed from the date of health screening until death.

Statistical Analysis {#s6}
--------------------

We computed the incidence rate of hospitalization for infection and infection-related mortality rate by diabetes status and by site of infection. We used Cox regression modeling to estimate the adjusted hazard ratios (aHRs) and corresponding 95% confidence intervals (95% CIs) for diabetes (compared to nondiabetes) and infection outcome (hospitalization and death), adjusting for potential confounders of age category, sex, current smoking, current drinking, low educational level, BMI category, systemic steroids use within 1 year before study entry, and hospitalization history within 6 months before hospitalization for infection. We further conducted a dose-response analysis stratifying by the level of FPG. The analysis of hospitalization for infection was conducted for all infections and by site of infection. In the analysis for specific site of infection, participants who were hospitalized due to 1 site of infection were not allowed to contribute follow-up person-time for another site of infection. In separate analyses, we classified both diabetes and nondiabetes groups according to their FPG levels and calculated the associated risks using nondiabetics and diabetics with FPG between 90--99 mg/dL as the reference group.

Because older people were more susceptible to infections, we further conducted a subgroup analysis on the association between FPG level and infection hospitalization among those aged above 65 years.

Several sensitivity analyses were conducted for a comprehensive evaluation of the relation between FPG and the risks of infection hospitalization. To avoid overadjustment of potential intermediate variables on a causal pathway between glycemic control and infection risk, we did not control for comorbidities in our main analysis. To further explore the role of comorbidities in the relation between FPG and infection morbidity and mortality, we additionally adjusted the Charlson comorbidity score to see if the association would change substantially. Because older adults (\>65 years old) and those with liver and renal disease, autoimmune disease, and cancer were more likely to have low FPG levels and also were more susceptible to severe infections, we excluded these participants to avoid confounding by these conditions. Because the definition of diabetes and glycemic control was based on 1 single measurement of FPG at baseline, we conducted the following analyses to reduce the potential biases from misclassification of blood glucose level. First, we excluded those with untreated diabetes (FPG \> 126 mg/dL but no prescription record for hypoglycemic agents) in order to remove the potential false-positive diabetes cases. Second, among the subgroup (\~9%) of population who had repeated measurements of FPG over multiple years, we used a time-dependent Cox analysis to account for time-varying exposure of FPG. Because prior study suggested an association between infection risk and recent rather than remote glycemic level \[[@CIT0006]\], we shortened the maximal follow-up period to 2 years after the baseline to avoid a long time lag between measurement of FPG and infection outcome. Lastly, because those who had early occult infections may have abnormal blood glucose levels, we conducted analyses excluding participants who were hospitalized for infections within 2 weeks after health screening program to reduce potential protopathic bias.

RESULTS {#s7}
=======

Of the total 118 645 study participants, 64% were women. The mean age was 51.9 years (standard deviation, 11.9) ([Table 1](#T1){ref-type="table"}). At the baseline, 9511 people (8.02%) had diabetes, and 59.8% of them were taking any antidiabetic medications. The prevalence of diabetes was 9.55% in men and 7.16% in women, respectively. Most of the diabetic participants included in our analysis had a duration of ≤4 years (mean diabetes duration, 2.1 years). In our study, only 3067 participants (2.6% of the total participants) had newly diagnosed diabetes. Among the diabetes patients, 29.07% had FPG \< 130 mg/dL, 60.35% had FPG between 130--200 mg/dL, and 10.58% had FPG \> 200 mg/dL. The differences in underlying disease between diabetic and nondiabetic participants can be seen in [Table 1](#T1){ref-type="table"}. As compared with nondiabetics, those diabetic patients with higher FPG were more likely to be overweight or obese and were more likely to use tobacco smoking and alcohol ([Table 1](#T1){ref-type="table"}), while a higher proportion of diabetic patients with FPG ≤ 90 mg/dL were male and elderly, had lower educational level, and more comorbidities.

###### 

Baseline Characteristics of the Study Population, Stratified by Diabetes Status and Fasting Plasma Glucose (mg/dl) Level

                                                             Total     No Diabetes   Diabetes, Overall   Diabetes, Stratified by FPG Level (mg/dl)                                                                              
  ---------------------------------------------------------- --------- ------------- ------------------- ------------------------------------------- ------ --------- ------ --------- ------ --------- ------ --------- ------ ---------
  **Characteristics**                                        118 645   (100.0%)      109 134             (92.0%)                                     9511   (8.0%)    174    (0.1%)    2591   (2.2%)    5740   (4.8%)    1006   (0.8%)
  Male                                                       42 380    (35.7%)       38 332              (35.1%)                                     4048   (42.6%)   85     (48.9%)   1163   (44.9%)   2401   (41.8%)   399    (39.7%)
  Age in year, mean (SD)                                     51.9      (11.9)        51.1                (11.7)                                      60.4   (10.7)    63.7   (10.4)    61.7   (11.0)    60.0   (10.7)    58.3   (10.1)
  Duration of diabetes in years, mean (SD)                   NA        NA            NA                  NA                                          2.08   (1.15)    2.12   (1.23)    2.02   (1.17)    2.10   (1.15)    2.10   (1.10)
   Newly diagnosed                                           3067      (2.6%)        NA                  NA                                          3067   (32.2%)   7      (4.0%)    598    (23.1%)   2159   (37.6%)   303    (30.1%)
   ≤4 years                                                  5902      (5.0%)        NA                  NA                                          5902   (62.1%)   146    (83.9%)   1822   (70.3%)   3288   (57.3%)   646    (64.2%)
   \>4 years                                                 542       (0.5%)        NA                  NA                                          542    (5.7%)    21     (12.1%)   171    (6.6%)    293    (5.1%)    57     (5.7%)
  Type 1 diabetes                                            NA        NA            NA                  NA                                          326    (3.4%)    9      5.2       92     3.6       181    3.2       44     4.4
  BMI (kg/m^2^), mean (SD)                                   24.4      (3.6)         24.2                (3.6)                                       26.3   (3.9)     25.1   (3.9)     26.2   (3.8)     26.5   (3.9)     26.0   (3.8)
   \<18.5                                                    3321      (2.8%)        3234                (3.0%)                                      87     (0.9%)    5      (2.9%)    22     (0.8%)    51     (0.9%)    9      (0.9%)
   18.5--25.0                                                68 876    (58.1%)       65 215              (59.8%)                                     3661   (38.5%)   93     (53.4%)   1006   (38.8%)   2144   (37.4%)   418    (41.6%)
   25.0--30.0                                                38 383    (32.4%)       34 123              (31.3%)                                     4260   (44.8%)   54     (31.0%)   1165   (45.0%)   2595   (45.2%)   446    (44.3%)
   \>30.0                                                    8065      (6.8%)        6562                (6.0%)                                      1503   (15.8%)   22     (12.6%)   398    (15.4%)   950    (16.6%)   133    (13.2%)
  Current smoker                                             17 548    (14.8%)       16 031              (14.7%)                                     1517   (15.9%)   31     (17.8%)   386    (14.9%)   903    (15.7%)   197    (19.6%)
  Current alcohol use                                        8429      (7.1%)        7647                (7.0%)                                      782    (8.2%)    13     (7.5%)    184    (7.1%)    475    (8.3%)    110    (10.9%)
  Education                                                                                                                                                                                                                     
   High school and above                                     58 291    (49.1%)       55 611              (51.0%)                                     2680   (28.2%)   38     (21.8%)   751    (29.0%)   1635   (28.5%)   256    (25.4%)
   Junior high school and below                              60 354    (50.9%)       53 523              (49.0%)                                     6831   (71.8%)   136    (78.2%)   1840   (71.0%)   4105   (71.5%)   750    (74.6%)
  Comorbidities                                                                                                                                                                                                                 
   Hypertension                                              21 755    (18.3%)       17 043              (15.6%)                                     4712   (49.5%)   113    (64.9%)   1451   (56.0%)   2700   (47.0%)   448    (44.5%)
   Ischemic heart disease                                    6992      (5.9%)        5575                (5.1%)                                      1417   (14.9%)   40     (23.0%)   453    (17.5%)   804    (14.0%)   120    (11.9%)
   Myocardial infarction                                     259       (0.2%)        195                 (0.2%)                                      64     (0.7%)    NA     NA        23     (0.9%)    37     (0.6%)    NA     NA
   Cardiac dysrhythmia                                       3208      (2.7%)        2771                (2.5%)                                      437    (4.6%)    12     (6.9%)    148    (5.7%)    245    (4.3%)    32     (3.2%)
   Congestive heart failure                                  1528      (1.3%)        1193                (1.1%)                                      335    (3.5%)    16     (9.2%)    120    (4.6%)    169    (2.9%)    30     (3.0%)
   Ischemic stroke                                           1417      (1.2%)        1100                (1.0%)                                      317    (3.3%)    10     (5.7%)    124    (4.8%)    159    (2.8%)    24     (2.4%)
   Hemorrhagic stroke                                        225       (0.2%)        197                 (0.2%)                                      28     (0.3%)    NA     NA        14     (0.5%)    10     (0.2%)    NA     NA
   Peripheral arterial disease                               511       (0.4%)        401                 (0.4%)                                      110    (1.2%)    3      (1.7%)    32     (1.2%)    65     (1.1%)    10     (1.0%)
   Lipid metabolism disorder                                 13 773    (11.6%)       10 469              (9.6%)                                      3304   (34.7%)   65     (37.4%)   1066   (41.1%)   1860   (32.4%)   313    (31.1%)
   Chronic lung disease                                      9068      (7.6%)        7947                (7.3%)                                      1121   (11.8%)   35     (20.1%)   338    (13.0%)   642    (11.2%)   106    (10.5%)
   Chronic liver disease                                     8397      (7.1%)        7337                (6.7%)                                      1060   (11.1%)   27     (15.5%)   325    (12.5%)   597    (10.4%)   111    (11.0%)
   Autoimmune disease                                        3179      (2.7%)        2873                (2.6%)                                      306    (3.2%)    4      (2.3%)    109    (4.2%)    170    (3.0%)    23     (2.3%)
   Dementia                                                  264       (0.2%)        203                 (0.2%)                                      61     (0.6%)    NA     NA        37     (1.4%)    21     (0.4%)    NA     NA
   Cancer                                                    2254      (1.9%)        1954                (1.8%)                                      300    (3.2%)    4      (2.3%)    111    (4.3%)    157    (2.7%)    28     (2.8%)
   Charlson comorbidity score, mean (SD)                     0.4       (0.9)         0.3                 (0.7)                                       1.40   (1.43)    2.3    (1.8)     1.6    (1.5)     1.3    (1.4)     1.3    (1.4)
  Systemic steroids use within 1 year prior to study entry   1523      (1.3%)        1330                (1.2%)                                      193    (2.0%)    9      (5.2%)    68     (2.6%)    101    (1.8%)    15     (1.5%)

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; SD, standard deviation.

NA indicates that the exact case number was too small to be retrieved because of the authority's policy regulation.

During a median follow up of 8.13 years, 14 372 cases of hospitalization for infection occurred. The most frequent site of infection was reproductive and urinary tract (5802), followed by lower respiratory tract (4052), septicemia (3255), intra-abdominal (1874), and skin and soft tissue (1856) ([Table 2](#T2){ref-type="table"}). The incidence rate of any infection was 36.33 (34.92--37.81) per 1000 person-years among diabetics and 14.26 (14.01--14.52) among nondiabetics. There were 5243 total deaths and 422 infection-related deaths during the follow-up period, with a rate of 15.39 (95% CI, 14.53--16.31) and 4.66 (95% CI, 4.52--4.80) per 1000 for overall mortality and 1.32 (1.08--1.61) and 0.37 (0.33--0.41) per 1000 for infection-related mortality among diabetics and nondiabetics, respectively ([Table 2](#T2){ref-type="table"}).

###### 

Association Between Fasting Plasma Glucose (mg/dl) Level at Baseline and the Risk of Infection Hospitalization by Site and Infection-Related Mortality Using Nondiabetics as the Reference Group

                                                                                                 No. of cases   Person-years   Incidence rate         Crude HR             Adjusted HR^a^       Adjusted HR^b^
  ----------------------------------------------------------------- ---------------------------- -------------- -------------- ---------------------- -------------------- -------------------- --------------------
  Any infection                                                     No DM                        11 938         837 015        14.26 (14.01\~14.52)   Reference            Reference            Reference
                                                                    DM                           2434           66 988         36.33 (34.92\~37.81)   2.56 (2.45\~2.67)    1.59 (1.52\~1.67)    1.33 (1.27\~1.39)
                                                                     DM and FPG ≤ 90             62             1094           56.70 (44.20\~72.72)   4.03 (3.14\~5.17)    1.89 (1.47\~2.42)    1.34 (1.04\~1.73)
                                                                     DM and 90 \< FPG ≤ 130      694            17 949         38.66 (35.89\~41.65)   2.73 (2.53\~2.95)    1.56 (1.45\~1.69)    1.27 (1.17\~1.37)
                                                                     DM and 130 \< FPG ≤ 200     1387           40 967         33.86 (32.12\~35.69)   2.38 (2.25\~2.52)    1.52 (1.43\~1.61)    1.29 (1.21\~1.37)
                                                                     DM and FPG \> 200           291            6978           41.70 (37.18\~46.78)   2.94 (2.61\~3.30)    2.09 (1.86\~2.35)    1.78 (1.58\~2.00)
  Septicemia                                                        No DM                        2592           837 015        3.10 (2.98\~3.22)      Reference            Reference            Reference
                                                                    DM                           663            66 988         9.90 (9.17\~10.68)     3.23 (2.96\~3.51)    1.86 (1.70\~2.03)    1.54 (1.40\~1.69)
                                                                     DM and FPG ≤ 90             19             1094           17.37 (11.08\~27.24)   5.77 (3.68\~9.06)    2.51 (1.60\~3.95)    1.77 (1.12\~2.79)
                                                                     DM and 90 \< FPG ≤ 130      188            17 949         10.47 (9.08\~12.08)    3.42 (2.95\~3.97)    1.82 (1.56\~2.11)    1.46 (1.25\~1.71)
                                                                     DM and 130 \< FPG ≤ 200     372            40 967         9.08 (8.20\~10.05)     2.95 (2.65\~3.29)    1.74 (1.56\~1.95)    1.47 (1.31\~1.65)
                                                                     DM and FPG \> 200           84             6978           12.04 (9.72\~14.91)    3.92 (3.16\~4.87)    2.61 (2.10\~3.24)    2.20 (1.77\~2.74)
  Lower respiratory tract infection                                 No DM                        3299           837 015        3.94 (3.81\~4.08)      Reference            Reference            Reference
                                                                    DM                           753            66 988         11.24 (10.47\~12.07)   2.88 (2.66\~3.12)    1.53 (1.41\~1.66)    1.25 (1.14\~1.36)
                                                                     DM and FPG ≤ 90             19             1094           17.37 (11.08\~27.24)   4.52 (2.88\~7.09)    1.55 (0.99\~2.43)    1.05 (0.67\~1.66)
                                                                     DM and 90 \< FPG ≤ 130      214            17 949         11.92 (10.43\~13.63)   3.06 (2.67\~3.52)    1.44 (1.25\~1.66)    1.14 (0.99\~1.31)
                                                                     DM and 130 \< FPG ≤ 200     432            40 967         10.54 (9.60\~11.59)    2.70 (2.44\~2.98)    1.50 (1.35\~1.66)    1.24 (1.11\~1.37)
                                                                     DM and FPG \> 200           88             6978           12.61 (10.23\~15.54)   3.23 (2.61\~3.99)    2.11 (1.70\~2.61)    1.76 (1.42\~2.18)
  Intra-abdominal infection                                         No DM                        1640           837 015        1.96 (1.87\~2.06)      Reference            Reference            Reference
                                                                    DM                           234            66 988         3.49 (3.07\~3.97)      1.79 (1.56\~2.05)    1.37 (1.19\~1.58)    1.20 (1.03\~1.39)
                                                                     DM and FPG ≤ 90             5              1094           4.57 (1.90\~10.99)     2.36 (0.98\~5.67)    1.54 (0.64\~3.70)    1.19 (0.49\~2.89)
                                                                     DM and 90 \< FPG \< ≤ 130   64             17 949         3.57 (2.79\~4.56)      1.83 (1.42\~2.35)    1.34 (1.04\~1.73)    1.15 (0.88\~1.49)
                                                                     DM and 130 \< FPG ≤ 200     135            40 967         3.30 (2.78\~3.90)      1.69 (1.41\~2.01)    1.31 (1.09\~1.56)    1.16 (0.97\~1.40)
                                                                     DM and FPG \> 200           30             6978           4.30 (3.01\~6.15)      2.20 (1.53\~3.16)    1.79 (1.25\~2.58)    1.59 (1.10\~2.29)
  Reproductive and urinary tract infection                          No DM                        4800           837 015        5.73 (5.57\~5.90)      Reference            Reference            Reference
                                                                    DM                           1002           66 988         14.96 (14.06\~15.91)   2.62 (2.44\~2.80)    1.79 (1.67\~1.92)    1.52 (1.41\~1.64)
                                                                     DM and FPG ≤ 90             18             1094           16.46 (10.37\~26.13)   2.90 (1.83\~4.61)    1.57 (0.99\~2.50)    1.15 (0.72\~1.83)
                                                                     DM and 90 \< FPG ≤ 130      290            17 949         16.16 (14.40\~18.13)   2.83 (2.51\~3.19)    1.81 (1.61\~2.05)    1.50 (1.32\~1.69)
                                                                     DM and 130 \< FPG ≤ 200     577            40 967         14.08 (12.98\~15.28)   2.46 (2.26\~2.68)    1.72 (1.57\~1.88)    1.48 (1.35\~1.62)
                                                                     DM and FPG \> 200           117            6978           16.77 (13.99\~20.10)   2.93 (2.44\~3.52)    2.25 (1.87\~2.70)    1.93 (1.61\~2.33)
  Skin and soft tissue infection, including necrotizing fasciitis   No DM                        1508           837 015        1.80 (1.71\~1.89)      Reference            Reference            Reference
                                                                    DM                           348            66 988         5.19 (4.68\~5.77)      2.89 (2.57\~3.25)    1.64 (1.45\~1.85)    1.35 (1.19\~1.54)
                                                                     DM and FPG ≤ 90             12             1094           10.97 (6.23\~19.32)    6.13 (3.48\~10.83)   2.84 (1.60\~5.01)    2.00 (1.12\~3.55)
                                                                     DM and 90 \< FPG ≤ 130      87             17 949         4.85 (3.93\~5.98)      2.70 (2.17\~3.35)    1.43 (1.15\~1.78)    1.14 (0.91\~1.43)
                                                                     DM and 130 \< FPG ≤ 200     200            40 967         4.88 (4.25\~5.61)      2.72 (2.34\~3.15)    1.56 (1.34\~1.82)    1.31 (1.12\~1.53)
                                                                     DM and FPG \> 200           49             6978           7.02 (5.31\~9.29)      3.91 (2.94\~5.19)    2.54 (1.91\~3.38)    2.12 (1.59\~2.84)
  Osteomyelitis                                                     No DM                        221            837 015        0.26 (0.23\~0.30)      Reference            Reference            Reference
                                                                    DM                           34             66 988         0.51 (0.36\~0.71)      1.91 (1.33\~2.74)    0.98 (0.68\~1.43)    0.85 (0.58\~1.26)
                                                                     DM and FPG ≤ 90             NA             1094           NA                     3.42 (0.48\~24.39)   1.29 (0.18\~9.23)    1.00 (0.14\~7.22)
                                                                     DM and 90 \< FPG ≤ 130      10             17 949         0.56 (0.30\~1.04)      2.10 (1.11\~3.96)    0.97 (0.51\~1.84)    0.82 (0.43\~1.58)
                                                                     DM and 130 \< FPG ≤ 200     17             40 967         0.41 (0.26\~0.67)      1.56 (0.95\~2.56)    0.83 (0.50\~1.37)    0.73 (0.44\~1.21)
                                                                     DM and FPG \> 200           NA             6978           NA                     3.23 (1.44\~7.27)    2.00 (0.89\~4.51)    1.78 (0.78\~4.03)
  Infection of central nervous system                               No DM                        NA             837 015        NA                     Reference            Reference            Reference
                                                                    DM                           NA             66 988         NA                     1.05 (0.25\~4.42)    0.93 (0.21\~4.10)    1.09 (0.24\~5.09)
                                                                     DM and FPG ≤ 90             0              1094           NA                     NA                   NA                   NA
                                                                     DM and 90 \< FPG ≤ 130      NA             17 949         NA                     3.91 (0.92\~16.55)   3.25 (0.72\~14.63)   4.04 (0.84\~19.53)
                                                                     DM and 130 \< FPG ≤ 200     0              40 967         NA                     NA                   NA                   NA
                                                                     DM and FPG \> 200           0              6978           NA                     NA                   NA                   NA
  Invasive fungal infection                                         No DM                        39             837 015        0.05 (0.03\~0.06)      Reference            Reference            Reference
                                                                    DM                           6              66 988         0.09 (0.04\~0.20)      1.94 (0.82\~4.59)    1.45 (0.59\~3.52)    1.08 (0.41\~2.85)
                                                                     DM and FPG ≤ 90             0              1094           NA                     NA                   NA                   NA
                                                                     DM and 90 \< FPG ≤ 130      NA             17 949         NA                     6.07 (2.39\~15.40)   4.39 (1.67\~11.53)   3.27 (1.19\~9.02)
                                                                     DM and 130 \< FPG ≤ 200     NA             40 967         NA                     0.53 (0.07\~3.85)    0.40 (0.05\~2.96)    0.27 (0.03\~2.18)
                                                                     DM and FPG \> 200           0              6978           NA                     NA                   NA                   NA
  Total mortality                                                   No DM                        4088           877 270        4.66 (4.52\~4.80)      Reference            Reference            Reference
                                                                    DM                           1155           75 034         15.39 (14.53\~16.31)   3.31 (3.10\~3.53)    1.69 (1.58\~1.81)    1.37 (1.27\~1.47)
                                                                     DM and FPG ≤ 90             35             1304           26.83 (19.27\~37.37)   6.37 (4.63\~8.77)    2.11 (1.53\~2.91)    1.45 (1.05\~2.00)
                                                                     DM and 90 \< FPG ≤ 130      355            20 166         17.60 (15.86\~19.53)   3.80 (3.41\~4.24)    1.71 (1.54\~1.91)    1.34 (1.20\~1.50)
                                                                     DM and 130 \< FPG ≤ 200     643            45 526         14.12 (13.07\~15.26)   3.03 (2.79\~3.29)    1.61 (1.48\~1.75)    1.33 (1.22\~1.45)
                                                                     DM and FPG \> 200           119            8038           14.80 (12.37\~17.72)   3.17 (2.64\~3.80)    2.01 (1.68\~2.42)    1.66 (1.38\~1.99)
  Mortality from any infection                                      No DM                        323            877 270        0.37 (0.33\~0.41)      Reference            Reference            Reference
                                                                    DM                           99             75 034         1.32 (1.08\~1.61)      3.59 (2.86\~4.49)    1.71 (1.36\~2.16)    1.45 (1.14\~1.85)
                                                                     DM and FPG ≤ 90             3              1304           2.30 (0.74\~7.13)      6.40 (2.06\~19.94)   1.78 (0.57\~5.57)    1.33 (0.42\~4.21)
                                                                     DM and 90 \< FPG ≤ 130      29             20 166         1.44 (1.00\~2.07)      3.95 (2.70\~5.77)    1.57 (1.07\~2.31)    1.30 (0.88\~1.92)
                                                                     DM and 130 \< FPG ≤ 200     52             45 526         1.14 (0.87\~1.50)      3.10 (2.31\~4.15)    1.56 (1.16\~2.10)    1.34 (0.99\~1.82)
                                                                     DM and FPG \> 200           15             8038           1.87 (1.13\~3.10)      5.03 (3.00\~8.45)    3.36 (1.99\~5.65)    2.87 (1.70\~4.86)

Abbreviations: DM, Diabetes mellitus; FPG, fasting plasma glucose; HR, hazard ratio.

NA indicates that the exact case number was too small to be retrieved, because of the authority's policy regulation or the hazard ratio could not be estimated.

^a^Adjusting for age (categorical), sex, tobacco smoking, alcohol use, education, body mass index (categorical), systemic steroids use 1 year before study entry, and hospitalization in the previous 6 months.

^b^Adjusting for age (categorical), sex, tobacco smoking, alcohol use, education, body mass index (categorical), systemic steroids use 1 year before study entry, hospitalization in the previous 6 months, and Charlson comorbidity score.

In the Cox regression analysis, the crude and adjusted HR of any hospitalization for infection comparing diabetics to nondiabetics was 2.56 (95% CI, 2.45--2.67) and 1.59 (95% CI, 1.52--1.67), respectively ([Table 2](#T2){ref-type="table"}). The association between diabetes and hospitalization for infection was similar across different sites of infection, except that the association between diabetes and osteomyelitis was weak and not statistically significant (aHR, 0.98; 95% CI, 0.68--1.43) and that between diabetes and invasive mold was not statistically significant (aHR, 1.45; 95% CI, 0.59--3.52). The aHR comparing diabetics to nondiabetics was 1.69 (95% CI, 1.58--1.81) for overall mortality and 1.71 (95% CI, 1.36--2.16) for infection-related mortality, respectively. Similar results were found in the analyses additionally controlled for Charlson comorbidity score, although the risk estimates associated with diabetes were slightly attenuated ([Table 2](#T2){ref-type="table"}).

Using FPG measured at baseline as a proxy for glycemic control, the HR for infection morbidity and mortality was higher at both extremes of FPG (\<90 mg/dL and \>200 mg/dL) with or without taking comorbidities into consideration ([Table 2](#T2){ref-type="table"}). Further detailed dose-response analysis of hospitalization for infection by 10 mg/dL interval of FPG revealed a U-shape curve ([Figure 1](#F1){ref-type="fig"}). The risks of hospitalization for infection among the diabetics across all FPG levels were uniformly higher than nondiabetics. A similar pattern was found between FPG level and infection-related mortality, but most of the associations were not statistically significant due to the few numbers of deaths from infection ([Figure 1](#F1){ref-type="fig"}).
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In a separate analysis using nondiabetics with FPG between 90--99 mg/dL as the reference group, a similar U-shaped curve was observed among the diabetics ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). Even at the same level of FPG, the infection risk among diabetics was consistently higher than that among the nondiabetics. In the nondiabetics, the risk of hospitalization for infection increased slightly at the 2 extremes (FPG \< 80 mg/dL and \>110 mg/dL). Importantly, the risk of infection was elevated in those with impaired fasting glucose (FPG between 100--126 mg/dL) when compared with nondiabetics with FPG between 90--99 mg/dL.

In older adults, the morbidity and mortality from infections were substantially increased when compared to the general population ([Table 3](#T3){ref-type="table"}). The incidence rate of any infection was 70.02 (95% CI, 66.32--73.92) and 45.21 (95% CI, 43.87--46.60) per 1000 person-years among diabetics and nondiabetics, respectively. The corresponding rate was 35.09 (95% CI, 32.73--37.62) and 23.64 (95% CI, 22.73--24.59) per 1000 for overall mortality, and 3.42 (95% CI, 2.73--4.27) and 2.49 (95% CI, 2.21--2.82) per 1000 for infection-related mortality among diabetics and nondiabetics, respectively. In the Cox regression analysis, the aHR of any hospitalization for infection, overall mortality, and infection-related mortality was 1.55 (95% CI, 1.45--1.65), 1.61 (95% CI, 1.48--1.74), and 1.59 (95% CI,1.23--2.06), respectively ([Table 3](#T3){ref-type="table"}). The risk estimates associated with diabetes were slightly attenuated after adjustment of comorbidity. The dose-response analysis of hospitalization for infection by 10 mg/dL interval of FPG also revealed a U-shape curve in this population ([Figure 2](#F2){ref-type="fig"}).

###### 

Association Between Fasting Plasma Glucose (mg/dl) Level at Baseline and the Risk of Infection Hospitalization by Site and Infection-Related Mortality Among Elderly Participants Aged \> 65 Years, Using Elderly Nondiabetics as the Reference Group

                                                                                                 No. of cases   Person-years   Incidence rate          Crude HR             Adjusted HR^a^       Adjusted HR^b^
  ----------------------------------------------------------------- ---------------------------- -------------- -------------- ----------------------- -------------------- -------------------- --------------------
  Any infection                                                     No DM                        4208           93 067         45.21 (43.87\~46.60)    Reference            Reference            Reference
                                                                    DM                           1304           18 624         70.02 (66.32\~73.92)    1.57 (1.47\~1.67)    1.55 (1.45\~1.65)    1.33 (1.24\~1.42)
                                                                     DM and FPG ≤ 90             38             497            76.42 (55.61\~105.02)   1.72 (1.25\~2.37)    1.65 (1.19\~2.27)    1.24 (0.90\~1.71)
                                                                     DM and 90 \< FPG ≤ 130      421            5911           71.23 (64.74\~78.37)    1.60 (1.45\~1.77)    1.54 (1.40\~1.71)    1.29 (1.17\~1.44)
                                                                     DM and 130 \< FPG ≤ 200     729            10 804         67.48 (62.75\~72.56)    1.51 (1.39\~1.63)    1.50 (1.39\~1.62)    1.31 (1.20\~1.42)
                                                                     DM and FPG \> 200           116            1412           82.14 (68.47\~98.54)    1.84 (1.53\~2.21)    1.92 (1.60\~2.31)    1.69 (1.40\~2.03)
  Septicemia                                                        No DM                        1037           93 067         11.14 (10.48\~11.84)    Reference            Reference            Reference
                                                                    DM                           343            18 624         18.42 (16.57\~20.47)    1.68 (1.48\~1.90)    1.69 (1.49\~1.91)    1.42 (1.25\~1.62)
                                                                     DM and FPG ≤ 90             13             497            26.14 (15.18\~45.02)    2.40 (1.39\~4.15)    2.34 (1.36\~4.05)    1.69 (0.97\~2.95)
                                                                     DM and 90 \< FPG ≤ 130      122            5911           20.64 (17.28\~24.65)    1.89 (1.56\~2.28)    1.87 (1.55\~2.25)    1.54 (1.27\~1.87)
                                                                     DM and 130 \< FPG ≤ 200     180            10 804         16.66 (14.40\~19.28)    1.51 (1.29\~1.77)    1.53 (1.30\~1.79)    1.31 (1.11\~1.55)
                                                                     DM and FPG \> 200           28             1412           19.83 (13.69\~28.72)    1.81 (1.24\~2.64)    1.93 (1.33\~2.82)    1.68 (1.15\~2.45)
  Lower respiratory tract infection                                 No DM                        1733           93 067         18.62 (17.76\~19.52)    Reference            Reference            Reference
                                                                    DM                           465            18 624         24.97 (22.80\~27.34)    1.36 (1.23\~1.51)    1.41 (1.27\~1.56)    1.19 (1.07\~1.33)
                                                                     DM and FPG ≤ 90             13             497            26.14 (15.18\~45.02)    1.44 (0.83\~2.48)    1.36 (0.79\~2.36)    1.00 (0.58\~1.74)
                                                                     DM and 90 \< FPG ≤ 130      145            5911           24.53 (20.85\~28.87)    1.34 (1.13\~1.59)    1.34 (1.13\~1.59)    1.11 (0.93\~1.32)
                                                                     DM and 130 \< FPG ≤ 200     269            10 804         24.90 (22.09\~28.06)    1.36 (1.19\~1.54)    1.41 (1.24\~1.61)    1.22 (1.07\~1.39)
                                                                     DM and FPG \> 200           38             1412           26.91 (19.58\~36.98)    1.47 (1.07\~2.03)    1.69 (1.22\~2.33)    1.47 (1.07\~2.04)
  Intra-abdominal infection                                         No DM                        340            93 067         3.65 (3.28\~4.06)       Reference            Reference            Reference
                                                                    DM                           95             18 624         5.10 (4.17\~6.24)       1.40 (1.12\~1.76)    1.39 (1.11\~1.75)    1.23 (0.97\~1.57)
                                                                     DM and FPG ≤ 90             NA             497            NA                      1.11 (0.28\~4.44)    1.06 (0.26\~4.26)    0.84 (0.21\~3.40)
                                                                     DM and 90 \< FPG \< ≤ 130   NA             5911           NA                      1.40 (0.96\~2.03)    1.36 (0.93\~1.98)    1.18 (0.80\~1.74)
                                                                     DM and 130 \< FPG ≤ 200     54             10 804         5.00 (3.83\~6.53)       1.37 (1.03\~1.83)    1.37 (1.02\~1.83)    1.23 (0.91\~1.65)
                                                                     DM and FPG \> 200           9              1412           6.37 (3.32\~12.25)      1.75 (0.90\~3.39)    1.84 (0.95\~3.57)    1.66 (0.85\~3.24)
  Reproductive and urinary tract infection                          No DM                        1445           93 067         15.53 (14.75\~16.35)    Reference            Reference            Reference
                                                                    DM                           556            18 624         29.85 (27.47\~32.44)    1.95 (1.77\~2.15)    1.88 (1.71\~2.08)    1.63 (1.47\~1.81)
                                                                     DM and FPG ≤ 90             13             497            26.14 (15.18\~45.02)    1.72 (0.99\~2.96)    1.65 (0.96\~2.85)    1.26 (0.73\~2.19)
                                                                     DM and 90 \< FPG ≤ 130      179            5911           30.28 (26.16\~35.06)    1.98 (1.70\~2.31)    1.88 (1.61\~2.20)    1.59 (1.36\~1.87)
                                                                     DM and 130 \< FPG ≤ 200     312            10 804         28.88 (25.85\~32.27)    1.88 (1.66\~2.13)    1.83 (1.62\~2.07)    1.60 (1.41\~1.82)
                                                                     DM and FPG \> 200           52             1412           36.82 (28.06\~48.32)    2.41 (1.83\~3.18)    2.38 (1.80\~3.14)    2.09 (1.58\~2.77)
  Skin and soft tissue infection, including necrotizing fasciitis   No DM                        504            93 067         5.42 (4.96\~5.91)       Reference            Reference            Reference
                                                                    DM                           164            18 624         8.81 (7.56\~10.26)      1.64 (1.37\~1.96)    1.53 (1.28\~1.83)    1.37 (1.13\~1.66)
                                                                     DM and FPG ≤ 90             6              497            12.07 (5.42\~26.86)     2.26 (1.01\~5.06)    2.23 (0.99\~4.99)    1.83 (0.81\~4.14)
                                                                     DM and 90 \< FPG ≤ 130      46             5911           7.78 (5.83\~10.39)      1.45 (1.07\~1.96)    1.34 (0.99\~1.81)    1.18 (0.87\~1.61)
                                                                     DM and 130 \< FPG ≤ 200     94             10 804         8.70 (7.11\~10.65)      1.62 (1.30\~2.02)    1.50 (1.20\~1.88)    1.36 (1.08\~1.71)
                                                                     DM and FPG \> 200           18             1412           12.75 (8.03\~20.23)     2.38 (1.49\~3.81)    2.33 (1.45\~3.73)    2.11 (1.31\~3.40)
  Osteomyelitis                                                     No DM                        87             93 067         0.93 (0.76\~1.15)       Reference            Reference            Reference
                                                                    DM                           15             18 624         0.81 (0.49\~1.34)       0.86 (0.50\~1.49)    0.80 (0.46\~1.39)    0.71 (0.40\~1.27)
                                                                     DM and FPG ≤ 90             0              497            NA                      NA                   NA                   NA
                                                                     DM and 90 \< FPG ≤ 130      5              5911           0.85 (0.35\~2.03)       0.90 (0.37\~2.22)    0.82 (0.33\~2.02)    0.71 (0.28\~1.79)
                                                                     DM and 130 \< FPG ≤ 200     NA             10 804         NA                      0.79 (0.38\~1.63)    0.75 (0.36\~1.55)    0.67 (0.32\~1.41)
                                                                     DM and FPG \> 200           NA             1412           NA                      1.51 (0.37\~6.14)    1.40 (0.34\~5.72)    1.27 (0.31\~5.22)
  Infection of central nervous system                               No DM                        4              93 067         0.04 (0.02\~0.11)       Reference            Reference            Reference
                                                                    DM                           0              18 624         NA                      NA                   NA                   NA
                                                                     DM and FPG ≤ 90             0              497            NA                      NA                   NA                   NA
                                                                     DM and 90 \< FPG ≤ 130      0              5911           NA                      NA                   NA                   NA
                                                                     DM and 130 \< FPG ≤ 200     0              10 804         NA                      NA                   NA                   NA
                                                                     DM and FPG \> 200           0              1412           NA                      NA                   NA                   NA
  Invasive fungal infection                                         No DM                        9              93 067         0.10 (0.05\~0.19)       Reference            Reference            Reference
                                                                    DM                           3              18 624         0.16 (0.05\~0.50)       1.68 (0.46\~6.22)    2.08 (0.55\~7.80)    1.86 (0.45\~7.63)
                                                                     DM and FPG ≤ 90             0              497            NA                      NA                   NA                   0.00 (0.00\~0.00)
                                                                     DM and 90 \< FPG ≤ 130      3              5911           0.51 (0.16\~1.57)       5.30 (1.43\~19.60)   6.98 (1.83\~26.53)   6.34 (1.49\~27.10)
                                                                     DM and 130 \< FPG ≤ 200     0              10 804         NA                      NA                   NA                   NA
                                                                     DM and FPG \> 200           0              1412           NA                      NA                   NA                   NA
  Total mortality                                                   No DM                        2483           105 043        23.64 (22.73\~24.59)    Reference            Reference            Reference
                                                                    DM                           791            22 543         35.09 (32.73\~37.62)    1.50 (1.38\~1.62)    1.61 (1.48\~1.74)    1.36 (1.25\~1.48)
                                                                     DM and FPG ≤ 90             26             609            42.67 (29.05\~62.67)    1.84 (1.25\~2.71)    1.90 (1.29\~2.79)    1.41 (0.95\~2.09)
                                                                     DM and 90 \< FPG ≤ 130      265            7137           37.13 (32.92\~41.88)    1.60 (1.41\~1.81)    1.63 (1.44\~1.86)    1.34 (1.17\~1.53)
                                                                     DM and 130 \< FPG ≤ 200     436            13 023         33.48 (30.48\~36.77)    1.43 (1.29\~1.58)    1.54 (1.39\~1.71)    1.34 (1.21\~1.49)
                                                                     DM and FPG \> 200           64             1773           36.11 (28.26\~46.13)    1.53 (1.19\~1.96)    1.86 (1.45\~2.39)    1.62 (1.26\~2.08)
  Mortality from any infection                                      No DM                        262            105 043        2.49 (2.21\~2.82)       Reference            Reference            Reference
                                                                    DM                           77             22 543         3.42 (2.73\~4.27)       1.39 (1.08\~1.80)    1.59 (1.23\~2.06)    1.43 (1.09\~1.87)
                                                                     DM and FPG ≤ 90             NA             609            NA                      1.35 (0.33\~5.41)    1.46 (0.36\~5.90)    1.21 (0.30\~4.94)
                                                                     DM and 90 \< FPG ≤ 130      NA             7137           NA                      1.50 (1.01\~2.25)    1.57 (1.05\~2.36)    1.37 (0.90\~2.08)
                                                                     DM and 130 \< FPG ≤ 200     40             13 023         3.07 (2.25\~4.19)       1.25 (0.89\~1.74)    1.46 (1.04\~2.05)    1.33 (0.94\~1.88)
                                                                     DM and FPG \> 200           9              1773           5.08 (2.64\~9.76)       2.04 (1.05\~3.96)    2.89 (1.48\~5.65)    2.64 (1.35\~5.18)

Abbreviations: DM, Diabetes mellitus; FPG, fasting plasma glucose; HR, hazard ratio.

NA indicates that the exact case number was too small to be retrieved, because of the authority's policy regulation or the hazard ratio could not be estimated.

^a^Adjusting for age (categorical), sex, tobacco smoking, alcohol use, education, body mass index (categorical), systemic steroids use 1 year before study entry, and hospitalization in the previous 6 months.

^b^Adjusting for age (categorical), sex, tobacco smoking, alcohol use, education, body mass index (categorical), systemic steroids use 1 year before study entry, hospitalization in the previous 6 months, and Charlson comorbidity score.
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We conducted additional analyses to compare the risk of hospitalization due to infection among all and elderly diabetic participants using diabetics with FPG 90--130 mg/dl as the reference group. As shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}, diabetic patients with FPG \> 200 mg/dl still were associated with a significantly higher risk, while those with FPG ≤ 90 mg/dl also were associated a similar magnitude of excess risk, although not attaining statistically significant. Similar findings were observed among elderly diabetic participants despite risks estimates that were not statistically significant due to smaller numbers of participants included in the analysis ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). After additionally controlling for Charlson comorbidity score, a slight increase in risk estimates for those diabetic patients with FPG \> 200 mg/dl and a decrease in risk estimates for those with FPG ≤ 90 mg/dl was observed ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). For elderly diabetic patients, those with FPG \> 200 mg/dl had a significantly higher risk of hospitalization for any infection after controlling for Charlson score ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). In contrast, the infection risk associated with FPG ≤ 90 mg/dl almost was abolished after controlling for Charlson score.

In a sensitivity analysis, the U-shape relation between FPG and infection risk among diabetics remained unchanged when we excluded those with untreated diabetes ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). We also reexamined the dose-response relation between FPG and infection risk after excluding the elderly (\>65 years old) and those with liver and renal disease, autoimmune disease, and cancer. The higher risk of infection at both extremes was still observed ([e Figure 4](#sup1){ref-type="supplementary-material"}). In a subset of our study population who had repeated measurement of FPG at least 1 year after the first measurement (\~9% of the original study population), the Pearson correlation coefficient between the first and second FPG measurement was 0.73 (*P* \< .001). The time-dependent Cox regression analysis in this subset revealed a similar dose-response relation between the FPG level and infection risk, but most of the associations were not statistically significant because of the much smaller sample size ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). No substantial changes in results were found when we excluded participants who were hospitalized for infections within 2 weeks after health screening program and shortened the maximal follow-up period to 2 years after the baseline ([Supplementary Figures 6 and 7](#sup1){ref-type="supplementary-material"}).

Discussion {#s8}
==========

In this large population-based community screening cohort, we found that diabetes was associated with not only an increased risk of hospitalization for infection, but also a higher risk of overall mortality and infection-related mortality. A U-shaped relation between FPG level and infection-related hospitalization and mortality was observed, and FPG level of \<90 mg/dL was associated with an increased risk of first hospitalization for infection and a trend of higher infection-related mortality. However, this increased risk was not observed when multiple comorbidities were further adjusted, suggesting that comorbidity may play a role in the excess risk associated with low FPG level. In the elderly, the hazard ratio between poor glycemic control and infection was similar to that observed in the general population. Given the high incidence rate of infection morbidity and mortality in the elderly, the absolute burden of infection attributable to poor glycemic control in this population would be substantial.

Prior studies in the United Kingdom and northern Denmark have reported that the risks of urinary tract infection, genital tract infection, hospitalization for pneumonia, and streptococci bacteremia were higher for diabetic patients compared with those without diabetes \[[@CIT0007]\]. In a Danish nationwide cohort study \[[@CIT0011]\], type 2 diabetic patients had a higher rate of hospital-treated infection during a median follow-up of 2.8 years, with a HR of 1.49 (95% CI, 1.47--1.52); the risks were increased particularly for urinary tract infection (HR, 1.41), skin infection (HR, 1.50), and septicemia (HR, 1.60). In a recent UK cohort, in comparison with patients without diabetes mellitus (DM), those with DM and optimal control (HbA1c 6--7%), and poor control (≥11%) had increased hospitalization risks for infection \[[@CIT0012]\]. We observed that diabetic patients had a nearly 60% increase in the risk of hospitalization for any infection, an approximately 80% excess risk of septicemia and urogenital tract infection, and a 64% higher risk of skin and soft tissue infection. The risk of hospitalization for infection became substantially higher in particular among those diabetic patients with FPG \> 200 mg/dL. Furthermore, we found that diabetics had a 71% elevated risk of infection-related mortality, while those with FPG level \> 200 mg/dL had a 3-fold increased risk of death due to infection as compared with those without diabetes.

In addition to the substantial evidence that high blood glucose level was associated with an elevated hazard, our study indicated that low blood glucose level also was associated with an increased risk of incident infection. Evidence on the dose-response relation between glycemic control and risk of infection has been limited and inconclusive \[[@CIT0013]\]. In the Diabetes Control and Complications Trial, intensive glucose control was associated with a nearly 50% reduction in vaginal infection among patients with type 1 diabetes. However, there was no association between glycemic control and the occurrence of foot, urinary, respiratory, and gastrointestinal infections \[[@CIT0014]\]. In a Dutch study of diabetic patients from general practices, the mean A1c level was similar in those with infection and those without infection \[[@CIT0015]\]. Another German study examined the relation between A1c and first occurrence of urinary tract infection. Compared with diabetic patients with A1c 7.0--7.5%, those with a high A1c level (\>9.5%) and those with a low A1c level of 6.0--6.5% were both associated with a significantly higher risk of infection \[[@CIT0005]\]. In a Denmark cohort of type 2 diabetics, Mor and colleagues also reported a J-shaped relation between blood glucose level and infection risk \[[@CIT0006]\].

Some researchers speculated that a higher infection risk for those diabetic patients with low blood glucose level may be due to malnutrition, multiple comorbidities, impaired kidney and liver function, and poor functional status or frailty. Nonetheless, a similar U-shape dose-response relation in our cohort remained even after excluding the elderly and those with liver, renal, and autoimmune diseases ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). Sufficient data have concluded that diabetic patients with low baseline A1c level was associated with an increased overall mortality \[[@CIT0016], [@CIT0017]\]. Several observational studies and 1 post-hoc analysis of a randomized trial also showed that hypoglycemia was associated with a higher risk of mortality and morbidity among diabetic patients hospitalized for infectious or noninfectious causes, in a critically ill or noncritically ill setting \[[@CIT0018]\]. To our knowledge, little is known about the effect of low blood glucose level on immune function in response to infections. Additional research is needed to explore the influence of hypoglycemia on infection among diabetics and the optimal level of glycemic control in terms of infection outcomes.

The strengths of this study included enrolling a large number of participants from a community health screening program and prospectively following them for several years. A comprehensive list of potential confounding factors, including BMI, educational level, smoking, and alcohol consumption, were considered in the analyses. Outcome occurrence was obtained by linkage to the National Health Insurance Database for any clinically important infection event with very low missing rate.

Several important limitations also should be considered in the present study. First, participants of this study were categorized based on a single measurement of FPG level instead of a series of hemoglobin A1c. Although the correlation between FPG level and A1c is generally good, exposure misclassification may still occur \[[@CIT0022]\]. We believe the misclassification bias of glycemic level would be nondifferential with regard to infection status, and this bias would have underestimated the true association between glycemic control and infection risk. Nonetheless, we excluded participants with untreated diabetes and considered time-varying glucose information among those who had repeated measurements of FPG level in the sensitivity analyses, and we found very similar results. Second, we could not exclude the possibility that physicians were more likely to admit diabetic patients or those with poorly controlled diabetes into the hospital for infectious disease management. However, this could not explain the observed increased risk of infection among those with low blood glucose. Third, although we have adjusted for major important risk factors, confounding from unmeasured variables, such as diabetes duration or socioeconomic status, may still possibly influence the results. Fourth, including only the first hospitalization as outcome, but not all hospitalization, would lose some statistical power. However, given the large sample size of the present study (14 372 cases of first hospitalizations), we still had sufficient power to analyze the dose-response relation between glucose level and infection hospitalization. We did not include all hospitalizations in our analysis, because there were assumptions while using either Poisson regression or negative binomial regression model for count data to handle overdispersion or underdispersion \[[@CIT0023], [@CIT0024]\]. Fifth, in this study, we described the relation between FPG and risk of hospitalization due to infection without applying any statistical test. Finally, whether our study findings can be generalized to whole population needs to be confirmed in the upcoming population-based studies or even randomized controlled trials.

Our study revealed that diabetes was associated with not only a higher risk of hospitalization for infection, but also a significantly increased risk of infection-related mortality both in the general population and in the elderly. A U-shaped relation between FPG level and infection-related outcome was observed. After controlling for comorbidity, the increased risk among those with low FPG was not observed, suggesting that multiple comorbidities may play a role in the excess risk associated with low FPG level. Fasting plasma glucose \> 200 mg/dl was consistently associated with a significantly higher risk of infection morbidity and mortality. We suggest that more efforts should be given to find the optimal level of glucose control to reduce the burden of infectious disease in diabetics, in particular for the elderly patients.
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